{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:38:51Z","timestamp":1790775531396,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fonds de recherche du Qu\u00e9bec \u2013 Sant\u00e9"},{"name":"Shriners of North America"},{"DOI":"10.13039\/501100007146","name":"AUVA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007146","id-type":"DOI","asserted-by":"crossref"}]},{"name":"WGKK"}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.bone.2014.06.015","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T16:30:35Z","timestamp":1403195435000},"page":"182-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta"],"prefix":"10.1016","volume":"66","author":[{"given":"Andreas","family":"Roschger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roschger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Keplingter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Klaushofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kneissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2014.06.015_bb0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bone.2014.06.015_bb0010","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2014.06.015_bb0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2014.06.015_bb0020","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nm.2388","article-title":"Lrp5 functions in bone to regulate bone mass","volume":"17","author":"Cui","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2014.06.015_bb0025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2014.06.015_bb0030","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.06.015_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.06.015_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","author":"Jacobsen","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.06.015_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","author":"Sinder","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.06.015_bb0050","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/jbmr.2177","article-title":"First mouse model for combined osteogenesis imperfecta and Ehlers\u2013Danlos syndrome","volume":"29","author":"Chen","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.06.015_bb0055","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.3390\/molecules16053675","article-title":"High affinity, developability and functional size: the holy grail of combinatorial antibody library generation","volume":"16","author":"Ponsel","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.bone.2014.06.015_bb0060","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jmb.2007.12.018","article-title":"The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies","volume":"376","author":"Rothe","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bone.2014.06.015_bb0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.06.015_bb0070","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S8756-3282(98)00112-4","article-title":"Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies","volume":"23","author":"Roschger","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.06.015_bb0075","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bone.2009.10.037","article-title":"CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII","volume":"46","author":"Fratzl-Zelman","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.06.015_bb0080","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.clinbiochem.2010.09.019","article-title":"Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay","volume":"43","author":"Koivula","year":"2010","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bone.2014.06.015_bb0085","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.clinbiochem.2012.03.035","article-title":"Measurement of C-terminal telopeptide of type I collagen (CTX) in serum","volume":"45","author":"Chubb","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bone.2014.06.015_bb0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.06.015_bb0095","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1359\/jbmr.080804","article-title":"Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors","volume":"23","author":"Uveges","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.06.015_bb0100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.06.015_bb0105","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bone.2006.02.071","article-title":"Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta","volume":"39","author":"Weber","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.06.015_bb0110","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00223-008-9113-x","article-title":"Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations","volume":"82","author":"Roschger","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2014.06.015_bb0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2013.11.023","article-title":"Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations","volume":"60","author":"Fratzl-Zelman","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.06.015_bb0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S8756-3282(01)00594-4","article-title":"Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim)","volume":"29","author":"Grabner","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.06.015_bb0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.06.015_bb0130","doi-asserted-by":"crossref","first-page":"E920","DOI":"10.1210\/jc.2013-3852","article-title":"Circulating sclerostin in children and young adults with heritable bone disorders","volume":"99","author":"Palomo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.06.015_bb0135","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1210\/jc.2013-2244","article-title":"Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta","volume":"99","author":"Kocijan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.06.015_bb0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214002245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214002245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T21:02:51Z","timestamp":1589230971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328214002245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":28,"alternative-id":["S8756328214002245"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2014.06.015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718464168.793509204","asserted-by":"object"}]},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2014.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}